KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $18.9 million.

  • Aquestive Therapeutics' Total Current Liabilities rose 68.78% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 68.78%. This contributed to the annual value of $18.9 million for FY2024, which is 3.04% up from last year.
  • As of FY2024, Aquestive Therapeutics' Total Current Liabilities stood at $18.9 million, which was up 3.04% from $18.3 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Total Current Liabilities registered a high of $39.5 million during FY2022, and its lowest value of $18.3 million during FY2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $18.9 million (2024), whereas its average is $25.6 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Total Current Liabilities soared by 79.97% in 2022 and then plummeted by 53.68% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Current Liabilities (Yearly) stood at $21.1 million in 2020, then climbed by 4.08% to $22.0 million in 2021, then spiked by 79.97% to $39.5 million in 2022, then plummeted by 53.68% to $18.3 million in 2023, then climbed by 3.04% to $18.9 million in 2024.